Skip to main content

Table 2 Associated Co-morbidities of Patients with and without Severe Vision Impairment/Blindness (SVI/B)

From: Severe vision impairment and blindness in hospitalized patients: a retrospective nationwide study

Co-morbidities Patients
without
SVI/B
N (%)
Patients
with
SVI/B
N (%)
p-value
Total 30,363,917 (99.8) 37,200 (0.2)  
Charlson comorbidity score    < 0.01
0 11,902,655 (39.2) 5,691 (15.3)  
1 5,860,235 (19.3) 5,914 (15.9)  
2 4,099,128 (13.5) 5,580 (15.0)  
3 or more 8,441,168 (27.8) 19,790 (53.2)  
Opioid use 637,642 (2.1) 446 (1.2) < 0.01
Tobacco use 5,222,593 (17.2) 3,720 (10.2) < 0.01
Alcohol use 1,366,376 (4.5) 706 (1.9) < 0.01
Depression 242,911 (0.8) 334 (0.9) 0.68
Chronic lung disease 4,736,771 (15.6) 5,914 (15.9) < 0.01
Hypertension 15,880,328 (52.3) 26,226 (70.5) < 0.01
Diabetes with complications* 4,433,131 (14.6) 14,619 (39.3) < 0.01
Peripheral vascular disease 1,457,468 (4.8) 3,980 (10.7) < 0.01
  1. SVI/B: Severe Vision Impairment/Blindness
  2. *Diabetes with complications. Complications include but not limited to retinopathy, neuropathy, nephropathy, foot ulcers (as described: https://www.icd10data.com/ICD10CM/Index/D/Diabetes%2c_diabetic#31090)